Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

ELTX Elicio Therapeutics Inc.

Price (delayed)

$7.69

Market cap

$123.02M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.92

Enterprise value

$109.77M

Highlights
ELTX's equity has surged by 179% since the previous quarter and by 83% year-on-year
ELTX's debt has shrunk by 78% QoQ and by 13% YoY
The quick ratio has decreased by 20% YoY but it has increased by 2.5% QoQ
The net income has declined by 32% year-on-year

Key stats

What are the main financial stats of ELTX
Market
Shares outstanding
16M
Market cap
$123.02M
Enterprise value
$109.77M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
13.78
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
Gross profit
$0
Operating income
-$45.48M
Net income
-$51.28M
EBIT
-$50.68M
EBITDA
-$49.52M
Free cash flow
-$35.15M
Per share
EPS
-$3.92
EPS diluted
-$3.92
Free cash flow per share
-$2.71
Book value per share
$0.56
Revenue per share
$0
TBVPS
$2.17
Balance sheet
Total assets
$28.14M
Total liabilities
$19.24M
Debt
$5.79M
Equity
$8.9M
Working capital
$9.52M
Liquidity
Debt to equity
0.65
Current ratio
1.83
Quick ratio
1.67
Net debt/EBITDA
0.27
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-185.7%
Return on equity
N/A
Return on invested capital
-306.1%
Return on capital employed
-302.9%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ELTX stock price

How has the Elicio Therapeutics stock price performed over time
Intraday
21.87%
1 week
43.47%
1 month
54.73%
1 year
-4.47%
YTD
50.78%
QTD
24.84%

Financial performance

How have Elicio Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$45.48M
Net income
-$51.28M
Gross margin
N/A
Net margin
N/A
The net income has declined by 32% year-on-year
The operating income has declined by 19% year-on-year

Price vs fundamentals

How does ELTX's price correlate with its fundamentals

Growth

What is Elicio Therapeutics's growth rate over time

Valuation

What is Elicio Therapeutics stock price valuation
P/E
N/A
P/B
13.78
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Elicio Therapeutics's EPS has increased by 25% YoY and by 8% from the previous quarter
ELTX's equity has surged by 179% since the previous quarter and by 83% year-on-year

Efficiency

How efficient is Elicio Therapeutics business performance
The company's return on assets fell by 43% YoY but it rose by 4.5% QoQ
ELTX's return on invested capital is down by 12% since the previous quarter

Dividends

What is ELTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ELTX.

Financial health

How did Elicio Therapeutics financials performed over time
The total assets is 46% greater than the total liabilities
ELTX's total liabilities has shrunk by 51% QoQ
The current ratio has contracted by 23% YoY
ELTX's debt is 35% lower than its equity
ELTX's equity has surged by 179% since the previous quarter and by 83% year-on-year
Elicio Therapeutics's debt to equity has soared by 128% from the previous quarter but it has plunged by 53% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.